Last reviewed · How we verify

Period I : CJ30001, Period II : HKB0701 and SLM0807

HK inno.N Corporation · Phase 1 active Small molecule Quality 0/100

Period I : CJ30001, Period II : HKB0701 and SLM0807 is a Small molecule drug developed by HK inno.N Corporation. It is currently in Phase 1 development.

At a glance

Generic namePeriod I : CJ30001, Period II : HKB0701 and SLM0807
SponsorHK inno.N Corporation
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Period I : CJ30001, Period II : HKB0701 and SLM0807

What is Period I : CJ30001, Period II : HKB0701 and SLM0807?

Period I : CJ30001, Period II : HKB0701 and SLM0807 is a Small molecule drug developed by HK inno.N Corporation.

Who makes Period I : CJ30001, Period II : HKB0701 and SLM0807?

Period I : CJ30001, Period II : HKB0701 and SLM0807 is developed by HK inno.N Corporation (see full HK inno.N Corporation pipeline at /company/hk-inno-n-corporation).

What development phase is Period I : CJ30001, Period II : HKB0701 and SLM0807 in?

Period I : CJ30001, Period II : HKB0701 and SLM0807 is in Phase 1.

Related